REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 3 filers reported holding REATA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $29,361,216 | +14.2% | 287,968 | +1.8% | 0.01% | +20.0% |
| Q1 2023 | $25,716,541 | +149.0% | 282,848 | +4.0% | 0.01% | +150.0% |
| Q4 2022 | $10,329,138 | +59.1% | 271,891 | +5.2% | 0.00% | +100.0% |
| Q3 2022 | $6,493,000 | -18.1% | 258,393 | -1.0% | 0.00% | -50.0% |
| Q2 2022 | $7,928,000 | -9.9% | 260,905 | -2.8% | 0.00% | 0.0% |
| Q1 2022 | $8,798,000 | +20.8% | 268,555 | -2.8% | 0.00% | +100.0% |
| Q4 2021 | $7,282,000 | -73.8% | 276,180 | -0.1% | 0.00% | -80.0% |
| Q3 2021 | $27,801,000 | -32.1% | 276,328 | -4.4% | 0.01% | -28.6% |
| Q2 2021 | $40,917,000 | +211.3% | 289,096 | +119.3% | 0.01% | +250.0% |
| Q1 2021 | $13,143,000 | -15.1% | 131,819 | +5.3% | 0.00% | -33.3% |
| Q4 2020 | $15,475,000 | +31.9% | 125,180 | +3.9% | 0.00% | 0.0% |
| Q3 2020 | $11,735,000 | -42.1% | 120,462 | -7.2% | 0.00% | -40.0% |
| Q2 2020 | $20,263,000 | -51.1% | 129,874 | -54.7% | 0.01% | -58.3% |
| Q1 2020 | $41,407,000 | -27.8% | 286,874 | +2.3% | 0.01% | -7.7% |
| Q4 2019 | $57,311,000 | +173.3% | 280,346 | +7.3% | 0.01% | +160.0% |
| Q3 2019 | $20,972,000 | -5.4% | 261,203 | +11.2% | 0.01% | 0.0% |
| Q2 2019 | $22,158,000 | +11.5% | 234,852 | +1.0% | 0.01% | 0.0% |
| Q1 2019 | $19,877,000 | +54.9% | 232,562 | +1.7% | 0.01% | +25.0% |
| Q4 2018 | $12,829,000 | -32.5% | 228,682 | -1.6% | 0.00% | -20.0% |
| Q3 2018 | $19,008,000 | +195.5% | 232,491 | +26.4% | 0.01% | +150.0% |
| Q2 2018 | $6,432,000 | +141.3% | 183,930 | +41.5% | 0.00% | +100.0% |
| Q1 2018 | $2,666,000 | -26.6% | 129,984 | +1.4% | 0.00% | 0.0% |
| Q4 2017 | $3,632,000 | -11.4% | 128,249 | -2.7% | 0.00% | 0.0% |
| Q3 2017 | $4,100,000 | +32.2% | 131,851 | +34.5% | 0.00% | 0.0% |
| Q2 2017 | $3,102,000 | +94.6% | 98,046 | +39.3% | 0.00% | – |
| Q1 2017 | $1,594,000 | +15.8% | 70,377 | +11.5% | 0.00% | – |
| Q4 2016 | $1,377,000 | -15.6% | 63,106 | +2.0% | 0.00% | -100.0% |
| Q3 2016 | $1,632,000 | +60.2% | 61,879 | +19.8% | 0.00% | – |
| Q2 2016 | $1,019,000 | – | 51,640 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |